Top Stories

Published on Tuesday, November 6, 2018

Mereo BioPharma and TAP work together in clinical study

Mereo BioPharma and TAP work together in clinical study

Mereo BioPharma Group plc announced a collaboration with (and investment from) the venture philanthropy arm of the Alpha-1 Foundation, The Alpha-1 Project, Inc. (TAP) in Mereo’s MPH-966 development program.

MPH-966 is an oral neutrophil elastase inhibitor that specifically targets the neutrophil elastase which is primarily responsible for the lung degradation in Alpha-1 patients.

TAP investment was announced in Mereo’s November 5th press release, publicizing that the first Alpha-1 patient was dosed in their Phase 2 clinical study of MPH-966 (alvelestat). The study is a 12-week randomized, placebo controlled, clinical trial evaluating two doses of MPH-966 in approximately 165 patients with the ZZ or NULL genetic mutations of Alpha-1. These mutations are associated with the more severely affected patients who have very low (ZZ) or zero (NULL) alpha-1 antitrypsin levels.

“We are very pleased that the first patient has been successfully dosed in this phase 2 study in Alpha-1 Antitrypsin Deficiency. We are excited by the potential for a new oral therapeutic to improve the lives of our patients with this debilitating disease and are pleased to be supporting Mereo with this phase 2 study,” said Jean-Marc Quach, president and CEO of TAP.

The study is being conducted in the United States and Europe with top line data expected in the second half of 2019. If the results are positive, Mereo intends to seek regulatory advice on the design of a pivotal trial.

To read the full press release, please click here.

Source: Mereo BioPharma Group plc


CSL augmentation therapy Respreeza approved for Alphas in Europe

Tuesday, August 25, 2015
Respreeza, CSL Behring's augmentation therapy for Alpha-1 Antitrypsin Deficiency, has been approved for use in Europe. The approval, following a clinical trial, came Thursday from the European Medicines Agency (EMA), the European equivalent of...

Teens who use e-cigarettes more likely to smoke later, study says

Wednesday, August 19, 2015
Teens who use e-cigarettes are more likely than others to later smoke conventional cigarettes and use other tobacco products, a study conducted at 10 Los Angeles high schools suggests. The study doesn’t prove that electronic cigarettes are...

Gene therapy in mice may one day help humans see better

Saturday, August 15, 2015
Gene therapy that has restored lost vision in mice could one day help restore human vision as well, a new study suggests.  Mice who lacked the protein retGC1, which is also deficient in humans suffering Leber congenital amaurosis-1 (LCA1)...

Study: Steroids may help speed pneumonia recovery

Tuesday, August 11, 2015
Steroid treatment may hasten pneumonia patients' recovery and cut their risk of complications, a new review suggests. The findings "should lead to an important change in treatment for pneumonia," lead author Dr. Reed Siemieniuk, a physician and...

FDA approves first COPD biomarker for use in clinical trials in "major triumph" for drug development

Monday, July 13, 2015
The U.S. Food and Drug Administration (FDA) has approved a new clinical biomarker, plasma fibrinogen, for use in clinical trials of patients with chronic obstructive pulmonary disease (COPD), the third leading cause of death in the United...

Foundation, NORD applaud House passage of 21st Century Cures Act, increasing NIH and FDA funding

Friday, July 10, 2015
The Alpha-1 Foundation and National Organization for Rare Disorders (NORD) today applauded the U.S. House for passing the 21st Century Cures Act legislation by a margin of 344-7. Peter Saltonstall, president and CEO of NORD, called the vote "a...

Foundation congratulates Alpha-1 pioneer researcher David Perlmutter on being named Washington University Medical School dean

Wednesday, July 8, 2015
The Alpha-1 Foundation today congratulated groundbreaking Alpha-1 researcher David Perlmutter, MD, on being named executive vice chancellor for medical affairs and dean of the Washington University School of Medicine in St. Louis, MO. Perlmutter,...

Alpha-1 Foundation announces funding opportunities for 2015-16 grants cycle with online application system

Wednesday, July 1, 2015
The Alpha-1 Foundation is now accepting applications for its 2015-16 grants cycle. Researchers, we hope you'll join the us in our quest to find treatments and a cure for Alpha-1 Antitrypsin Deficiency. The Foundation committed nearly $2...

Research Registry Update summer issue tells you what's happening in Alpha-1 research, how you can sign up

Tuesday, June 30, 2015
A new issue of the Alpha-1 Foundation's Research Registry Update has been mailed out to all of the Registry's more than 4,800 members. As always, the Registry Update presents information on the current research studies being managed by the...

What will happen to state-run insurance exchanges?

Monday, June 29, 2015
The Supreme Court upheld a key part of the Affordable Care Act on Thursday, enabling health insurance subsidies to all qualifying Americans. The ruling firmly establishes the legality of Obamacare, but quite a few states had already moved...

Committee recommends European Medicines Agency approve CSL's Alpha-1 augmentation therapy

Monday, June 29, 2015
A key committee has recommended that the European Medicines Agency (EMA) approve Respreeza, CSL Behring's augmentation therapy for Alpha-1 Antitrypsin Deficiency. The EMA is the European equivalent of the U.S. Food and Drug Administration...

US Supreme Court upholds the Affordable Healthcare Act

Thursday, June 25, 2015
Washington, DC -  Obamacare has survived -- again. In a 6-3 decision, the Supreme Court saved the controversial health care law that will define President Barack Obama's administration for generations to come. The ruling holds that the...

Article Search

Enter keywords in text box and click Search button for results.